TScan Therapeutics, Inc. (NASDAQ:TCRX) Given Average Rating of “Hold” by Analysts

Shares of TScan Therapeutics, Inc. (NASDAQ:TCRX) have been given an average recommendation of “Hold” by the seven brokerages that are currently covering the company, MarketBeat Ratings reports. One analyst has rated the stock with a sell recommendation, two have given a hold recommendation and four have issued a buy recommendation on the company. The average 1 year price target among analysts that have issued a report on the stock in the last year is $6.00.

TCRX has been the subject of a number of research reports. Benchmark restated a “buy” rating on shares of TScan Therapeutics in a report on Thursday, August 13th. Wall Street Zen lowered shares of TScan Therapeutics from a “sell” rating to a “strong sell” rating in a report on Saturday, May 9th. Weiss Ratings reissued a “sell (d-)” rating on shares of TScan Therapeutics in a research report on Friday, July 17th. HC Wainwright restated a “buy” rating on shares of TScan Therapeutics in a research note on Wednesday, August 12th. Finally, Wedbush reaffirmed an “outperform” rating and issued a $5.00 target price on shares of TScan Therapeutics in a research report on Tuesday, June 23rd.

TScan Therapeutics Stock Performance

Shares of TCRX stock opened at $0.75 on Thursday. The company has a market cap of $49.01 million, a price-to-earnings ratio of -0.82 and a beta of 1.06. TScan Therapeutics has a 52 week low of $0.72 and a 52 week high of $2.57. The company has a quick ratio of 3.37, a current ratio of 3.37 and a debt-to-equity ratio of 0.31. The firm has a 50 day moving average of $0.89 and a 200-day moving average of $1.01.

TScan Therapeutics (NASDAQ:TCRX) last released its quarterly earnings data on Wednesday, August 12th. The company reported ($0.23) earnings per share for the quarter, beating the consensus estimate of ($0.25) by $0.02. TScan Therapeutics had a negative net margin of 1,655.35% and a negative return on equity of 108.72%. The company had revenue of $1.05 million during the quarter, compared to analyst estimates of $1.88 million. On average, equities analysts forecast that TScan Therapeutics will post -1.12 earnings per share for the current year.

Institutional Investors Weigh In On TScan Therapeutics

A number of hedge funds have recently added to or reduced their stakes in TCRX. Goldman Sachs Group Inc. increased its holdings in shares of TScan Therapeutics by 6.0% during the first quarter. Goldman Sachs Group Inc. now owns 170,349 shares of the company’s stock valued at $235,000 after acquiring an additional 9,676 shares in the last quarter. JPMorgan Chase & Co. lifted its holdings in shares of TScan Therapeutics by 8.5% in the 2nd quarter. JPMorgan Chase & Co. now owns 287,743 shares of the company’s stock worth $417,000 after purchasing an additional 22,642 shares in the last quarter. Marshall Wace LLP bought a new position in shares of TScan Therapeutics in the 2nd quarter worth $78,000. Qube Research & Technologies Ltd acquired a new stake in TScan Therapeutics in the 2nd quarter valued at $99,000. Finally, Jane Street Group LLC acquired a new stake in TScan Therapeutics in the 2nd quarter valued at $309,000. Institutional investors and hedge funds own 82.83% of the company’s stock.

About TScan Therapeutics

TScan Therapeutics is a clinical-stage biotechnology company focused on the discovery and development of T-cell receptor (TCR) therapies for the treatment of cancer. Leveraging its proprietary T-Scan platform, the company seeks to identify high-affinity TCRs that recognize intracellular tumor antigens presented on the surface of cancer cells. TScan’s approach aims to broaden the reach of immunotherapy beyond current targets by unlocking a wider array of cancer-associated proteins.

The company’s pipeline includes multiple preclinical and early-stage clinical programs in both hematologic malignancies and solid tumors.